Abstract
The aim of the present paper is to provide information concerning the setting up and interpretation of therapeutic drug monitoring (TDM) for anti-epileptic drugs. The potential value of TDM for these drugs (including carbamazepine, clobazam, clonazepam, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pheneturide, phenobarbital, phenytoin, primidone, tiagabine, topiramate, valproic acid, vigabatrin and zonisamide) is discussed in relation to their mode of action, drug interactions and their pharmacokinetic properties. The review is based upon available literature data and on observations from our clinical practice. Up until approximately 15 years ago anti-epileptic therapeutics were restricted to a very few drugs that were developed in the first half of the 20th century. Unfortunately, many patients were refractory to these drugs and a new generation of drugs has been developed, mostly as add-on therapy. Although the efficacy of the newer drugs is no better, there is an apparent improvement in drug tolerance, combined with a diminished potential for adverse drug interactions. All new anticonvulsant drugs have undergone extensive clinical studies, but information on the relationship between plasma concentrations and effects is scarce for many of these drugs. Wide ranges in concentrations have been published for seizure control and toxicity. Few studies have been undertaken to establish the concentration-effect relationship. This review shows that TDM may be helpful for a number of these newer drugs.
References
1 Shorvon SD. Epidemiology, classification, natural history, and genetics of epilepsy. Lancet 1990; 336:93–6.10.1016/0140-6736(90)91603-8Search in Google Scholar
2 Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940–1980. Epilepsia 1991; 32:429–45.10.1111/j.1528-1157.1991.tb04675.xSearch in Google Scholar
3 Berkovic SF, Scheffer IE. Genetics of the epilepsies. Epilepsia 2001; 42:16–23.10.1111/j.1528-1167.2001.0s003.xSearch in Google Scholar
4 Stafstrom CE, Tempel BL. Epilepsy genes: the link between molecular dysfunction and pathophysiology. Ment Retard Dev Disabil Res Rev 2000; 6:281–92.10.1002/1098-2779(2000)6:4<281::AID-MRDD7>3.0.CO;2-9Search in Google Scholar
5 Burgess DL, Noebels JL. Single gene defects in mice: the role of voltage-dependent calcium channels in absence models. Epilepsy Res 1999; 36:111–22.10.1016/S0920-1211(99)00045-5Search in Google Scholar
6 Kim D, Song I, Keum S, Lee T, Jeong MJ, Kim SS, et al. Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking alpha(1G) T-type Ca2+ channels. Neuron 2001; 31:35–45.10.1016/S0896-6273(01)00343-9Search in Google Scholar
7 Chang BS, Lowenstein DH. Epilepsy. N Engl J Med 2003; 349:1257–66.10.1056/NEJMra022308Search in Google Scholar
8 Engel J. Mesial temporal lobe epilepsy: what have we learned? Neuroscientist 2001; 7:340–52.10.1177/107385840100700410Search in Google Scholar
9 Benbadis SR. Epileptic seizures and syndromes. Neurol Clin 2001; 19:251–70.10.1016/S0733-8619(05)70018-9Search in Google Scholar
10 Royal Pharmaceutical Society of GB. Antiepileptics. In: Martindale: the extra pharmacopoeia, 33rd ed. London: Pharmaceutical Press, 2002:338 pp.Search in Google Scholar
11 Huff JS, Morris DL, Kothari RU, Gibbs MA. Emergency department management of patients with seizures: a multicenter study. Acad Emerg Med 2001; 8:622–8.10.1111/j.1553-2712.2001.tb00175.xSearch in Google Scholar
12 Wet Inst Ned Apothekers. Infomatorium medicamentorum. Den Haag, Nederland: Koninklijke Nederlandse Vereniging ter Bevordering der Pharmacie, 2004:203 pp.Search in Google Scholar
13 Brodie MJ, Dichter MA. Drug therapy – antiepileptic drugs. N Engl J Med 1996; 334:168–75.10.1056/NEJM199601183340308Search in Google Scholar PubMed
14 Devinsky O. Patients with refractory seizures. N Engl J Med 1999; 340:1565–70.10.1056/NEJM199905203402008Search in Google Scholar PubMed
15 Patsalos PN. Antiepileptic drug pharmacokinetics. Ther Drug Monit 2000; 22:127–30.10.1097/00007691-200002000-00027Search in Google Scholar PubMed
16 Clancy CE, Kass RS. Pharmacogenomics in the treatment of epilepsy. Pharmacogenomics 2003; 4:747–51.10.1517/phgs.4.6.747.22822Search in Google Scholar PubMed
17 Desta Z, Zhao X, Shin J-G, FLockhart D. Clinical significance of the cytochrome P4502C19 genetic polymorphism. Clin Pharmacokinet 2002; 41:913–58.10.2165/00003088-200241120-00002Search in Google Scholar PubMed
18 Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000; 38:191–204.10.2165/00003088-200038030-00001Search in Google Scholar PubMed
19 Patsalos PN. New antiepileptic drugs. Ann Clin Biochem 1999; 36:10–9.10.1177/000456329903600102Search in Google Scholar PubMed
20 Shorvon SD, Chadwick D, Galbraith AW, Reynolds EH. One drug for epilepsy. Br Med J 1978; 1:474–6.10.1136/bmj.1.6111.474Search in Google Scholar PubMed PubMed Central
21 Eadie MJ. Plasma antiepileptic drug-monitoring in a neurological practice – a 25-year experience. Ther Drug Monit 1994; 16:458–68.10.1097/00007691-199410000-00004Search in Google Scholar PubMed
22 Chadwick DW. Overuse of monitoring of blood concentrations of antiepileptic drugs. Br Med J 1987; 294:723–4.10.1136/bmj.294.6574.723Search in Google Scholar PubMed PubMed Central
23 Moyer T. Therapeutic drug monitoring. In: Burtis C, Ashwood E, editors. Tietz textbook of clinical chemistry. WB Saunders, 1999:862 pp.Search in Google Scholar
24 Dasgupta A. Clinical utility of free drug monitoring. Clin Chem Lab Med 2002; 40:986–93.10.1515/CCLM.2002.172Search in Google Scholar PubMed
25 Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples – focus on anticonvulsants. Clin Pharmacokinet 1999; 36:453–70.10.2165/00003088-199936060-00006Search in Google Scholar PubMed
26 Choo RE, Huestis MA. Oral fluid as a diagnostic tool. Clin Chem Lab Med 2004; 42:1273–87.Search in Google Scholar
27 Tarasidis CG, Garnett WR, Kline BJ, Pellock JM. Influence of tube type, storage time and temperature on the total and free concentration of valproic acid. Ther Drug Monit 1986; 8:373–6.10.1097/00007691-198609000-00025Search in Google Scholar PubMed
28 Ohshima T, Hasegawa T, Johno I, Kitazawa S. Variations in protein binding of drugs in plasma and urine. Clin Chem 1989; 35:1722–5.10.1093/clinchem/35.8.1722Search in Google Scholar
29 Warner A, Privitera M, Bates D. Standards of laboratory practice: antiepileptic drug monitoring. Clin Chem 1998; 44:1085–95.10.1093/clinchem/44.5.1085Search in Google Scholar
30 Dasgupta A, Dean R, Saldana S, Konnaman G, McLawhon RW. Absorption of therapeutic drugs by barrier gels in serum separator blood collection tubes. Am J Clin Pathol 1994; 101:456–61.10.1093/ajcp/101.4.456Search in Google Scholar PubMed
31 Karppi J, Akerman KK, Parviainen M. Suitability of collection tubes with separator gels for collecting and storing blood samples for therapeutic drug monitoring (TDM). Clin Chem Lab Med 2000; 38:313–20.10.1515/CCLM.2000.045Search in Google Scholar PubMed
32 Koch TR, Platoff G. Suitability of collection tubes with separator gels for therapeutic drug monitoring. Ther Drug Monit 1990; 12:277–80.10.1097/00007691-199005000-00011Search in Google Scholar PubMed
33 Landt M, Smith CH, Hortin GL. Evaluation of evacuated blood-collection tubes: effects of three types of polymeric separators on therapeutic drug-monitoring specimens. Clin Chem 1993; 39:1712–7.10.1093/clinchem/39.8.1712Search in Google Scholar
34 Contin M, Riva R, Albani F, Perucca E, Baruzzi A. Determination of total and free plasma carbamazepine concentrations by enzyme multiplied immunoassay: interference with the 10,11-epoxide metabolite. Ther Drug Monit 1985; 7:46–50.10.1097/00007691-198503000-00007Search in Google Scholar PubMed
35 Roberts WL, Rainey PM. Interference in immunoassay measurements of total and free phenytoin in uremic patients: a reappraisal. Clin Chem 1993; 39:1872–7.10.1093/clinchem/39.9.1872Search in Google Scholar
36 Kricka L. Principles of immunochemical techniques. In: Burtis C, Ashwood E, editors. Tietz textbook of clinical chemistry. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo: WB Saunders, 1999:205 pp.Search in Google Scholar
37 Soldin SJ, Hill JG. Rapid micromethod for measuring anticonvulsant drugs in serum by high-performance liquid-chromatography. Clin Chem 1976; 22:856–9.10.1093/clinchem/22.6.856Search in Google Scholar
38 Kabra PM, Stafford BE, Marton LJ. Simultaneous measurement of phenobarbital, phenytoin, primidone, ethosuximide, and carbamazepine in serum by high-pressure liquid chromatography. Clin Chem 1977; 23:1284–8.10.1093/clinchem/23.7.1284Search in Google Scholar
39 Neels HM, Totté JA, Verkerk RM, Vlietinck AJ, Scharpé SL. Simultaneous high performance liquid-chromatographic determination of carbamazepine, carbamazepine-10,11-epoxide, ethosuximide, phenobarbital, phenytoin, primidone and phenylethylmalonamide in plasma. J Clin Chem Clin Biochem 1983; 21:295–9.Search in Google Scholar
40 Levert H, Odou P, Robert H. Simultaneous determination of four antiepileptic drugs in serum by high-performance liquid chromatography. Biomed Chromatogr 2002; 16:19–24.10.1002/bmc.117Search in Google Scholar
41 Herzler M, Herre S, Pragst F. Selectivity of substance identification by HPLC-DAD in toxicological analysis using a UV spectra library of 2682 compounds. J Anal Toxicol 2003; 27:233–42.10.1093/jat/27.4.233Search in Google Scholar
42 Pragst F, Herzler M, Herre S, Erxleben T, Rothe M. UV spectra of toxic compounds, 4th ed. Verlag Dieter Helm Heppenheim, 2001.Search in Google Scholar
43 Pragst F, Herzler M, Erxleben B-T. Systematic toxicological analysis by high performance liquid chromatography with diode array detection (HPLC-DAD). Clin Chem Lab Med 2004; 42:1325–40.10.1515/CCLM.2004.251Search in Google Scholar
44 McLean MJ, McDonald RL. Carbamazepine and 10,11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapid firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986; 238:727–38.Search in Google Scholar
45 Dichter MA. Old and new mechanisms of antiepileptic drug actions. Epilepsy Res 1993; 10S:9–17.Search in Google Scholar
46 McNamara JO. Drugs effective in the therapy of the epilepsies. In: Hardman JE, Limbird LE, Goodman Gillman A, editors. The pharmacological basis of therapeutics, 10th ed. McGraw-Hill, 2001:521 pp.Search in Google Scholar
47 Brodie MJ. Drug interactions in epilepsy. Epilepsia 1992; 33:S13–22.10.1111/j.1528-1157.1992.tb05896.xSearch in Google Scholar
48 Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. J Am Med Assoc 1986; 256:238–40.10.1001/jama.1986.03380020100031Search in Google Scholar
49 Shen S, Elin RJ, Soldin SJ. Characterization of cross reactivity by carbamazepine-10,11-epoxide with carbamazepine assays. Clin Biochem 2001; 34:157–8.10.1016/S0009-9120(01)00186-2Search in Google Scholar
50 Brodie MJ, Feely J. Practical clinical pharmacology – therapeutic drug monitoring and clinical trials. Br Med J 1988; 296:1110–4.10.1136/bmj.296.6629.1110Search in Google Scholar
51 Richens A, Davidson DLW, Cartlidge NEF, Easter DJ. A multicenter comparative trial of sodium valproate and carbamazepine in adult-onset epilepsy. J Neurol Neurosurg Psychiatry 1994; 57:682–7.10.1136/jnnp.57.6.682Search in Google Scholar
52 Hermida J, Tutor JC. How suitable are currently used carbamazepine immunoassays for quantifying carbamazepine-10,11-epoxide in serum samples? Ther Drug Monit 2003; 25:384–8.10.1097/00007691-200306000-00021Search in Google Scholar
53 Ranise A, Benassi E, Besio G. Rapid gas chromatography method for the determination of carbamazepine and unrearranged carbamazepine-10,11-epoxide in human plasma. J Chromatogr 1981; 222:120–4.10.1016/S0378-4347(00)81040-3Search in Google Scholar
54 Hallbach J, Vogel H, Guder WG. Determination of lamotrigine, carbamazepine and carbamazepine epoxide in human serum by gas chromatography mass spectrometry. Eur J Clin Chem Clin Biochem 1997; 35:755–9.10.1515/cclm.1997.35.10.755Search in Google Scholar PubMed
55 Rambeck B, May TW, Jurgens MU, Blankenhorn V, Jurges U, Korn-Merker E, et al. Comparison of phenytoin and carbamazepine serum concentrations measured by high-performance liquid chromatography, the standard TDx assay, the enzyme multiplied immunoassay technique, and a new patient-side immunoassay cartridge system. Ther Drug Monit 1994; 16:608–12.10.1097/00007691-199412000-00013Search in Google Scholar PubMed
56 Shimoyama R, Ohkubo T, Sugawara K. Monitoring of carbamazepine and carbamazepine-10,11-epoxide in breast milk and plasma by high-performance liquid chromatography. Ann Clin Biochem 2000; 37:210–5.10.1258/0004563001899023Search in Google Scholar PubMed
57 Dichter MA, Brodie MJ. Drug therapy – new antiepileptic drugs. N Engl J Med 1996; 334:1583–90.10.1056/NEJM199606133342407Search in Google Scholar PubMed
58 Robertson MM. Current status of the 1,4-benzodiazepines and 1,5-benzodiazepines in the treatment of epilepsy – the place of clobazam. Epilepsia 1986; 27:S27–41.10.1111/j.1528-1157.1986.tb05730.xSearch in Google Scholar PubMed
59 Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy. Epilepsia 1998; 39:952–9.10.1111/j.1528-1157.1998.tb01444.xSearch in Google Scholar PubMed
60 Marson AG, Chadwick DW. Report of a pragmatic trial comparing clobazam and ‘standard’ treatment in childhood epilepsy. Epilepsia 1999; 40:531–3.Search in Google Scholar
61 Haefely W, Kulcsar A, Mohler H, Pieri L, Polc P, Schaffner R. Possible involvement of GABA in the central actions of benzodiazepines. Adv Biochem Psychopharmacol 1975; 14:131–51.Search in Google Scholar
62 Pullar T, Haigh JRM, Peaker S, Feely MP. Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy. Br J Clin Pharmacol 1987; 24:793–7.10.1111/j.1365-2125.1987.tb03247.xSearch in Google Scholar PubMed PubMed Central
63 Contin M, Sangiorgi S, Riva R, Parmeggiani A, Albani F, Baruzzi A. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther Drug Monit 2002; 24:736–41.10.1097/00007691-200212000-00009Search in Google Scholar
64 Schutz H. Benzodiazepines II. Berlin, Heidelberg, New York, London, Paris, Tokyo: Springer-Verlag, 1989.Search in Google Scholar
65 Greenblatt DJ. Electron-capture GLC determination of clobazam and desmethylclobazam in plasma. J Pharm Sci 1980; 69:1351–2.10.1002/jps.2600691131Search in Google Scholar
66 Lillsunde P, Seppala T. Simultaneous screening and quantitative analysis of benzodiazepines by dual-channel gas-chromatography using electron-capture and nitrogen phosphorus detection. J Chromatogr 1990; 533:97–110.10.1016/S0378-4347(00)82190-8Search in Google Scholar
67 Brachetliermain A, Jarry C, Faure O, Guyot M, Loiseau P. Liquid-chromatography determination of clobazam and its major metabolite N-desmethylclobazam in human plasma. Ther Drug Monit 1982; 4:301–5.10.1097/00007691-198208000-00009Search in Google Scholar
68 Kunicki PK. Simple and sensitive high-performance liquid chromatographic method for the determination of 1,5-benzodiazepine clobazam and its active metabolite N-desmethylclobazam in human serum and urine with application to 1,4-benzodiazepines analysis. J Chromatogr 2001; 750:41–9.10.1016/S0378-4347(00)00391-1Search in Google Scholar
69 Naito H, Wachi M, Nishida M. Clinical effects and plasma concentrations of long-term clonazepam monotherapy in previously untreated epileptics. Acta Neurol Scand 1987; 76:58–63.10.1111/j.1600-0404.1987.tb03545.xSearch in Google Scholar
70 Specht U, Boenigk HE, Wolf P. Discontinuation of clonazepam after long-term treatment. Epilepsia 1989; 30:458–63.10.1111/j.1528-1157.1989.tb05326.xSearch in Google Scholar
71 Cohen LS, Rosenbaum JF. Clonazepam: new uses and potential problems. J Clin Psychiatry 1987; 48:50–5.Search in Google Scholar
72 de Boer AG, Rost-Kaiser J, Bracht H, Breimer DD. Assay of underivatized nitrazepam and clonazepam in plasma by capillary gas chromatography applied to pharmacokinetic and bioavailability studies in humans. J Chromatogr 1978; 145:105–14.10.1016/S0378-4347(00)81672-2Search in Google Scholar
73 Song D, Zhang S, Kohlhof K. Quantitative determination of clonazepam in plasma by gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr B Biomed Appl 1996; 686:199–204.10.1016/S0378-4347(96)00215-0Search in Google Scholar
74 Robertson MD, Drummer OH. High-performance liquid-chromatographic procedure for the measurement of nitrobenzodiazepines and their 7-amino metabolites in blood. J Chromatogr B Biomed Appl 1995; 667:179–84.10.1016/0378-4347(95)00017-DSearch in Google Scholar
75 El Mahjoub A, Staub C. Determination of benzodiazepines in human hair by on-line high-performance liquid chromatography using a restricted access extraction column. Forensic Sci Int 2001; 123:17–25.10.1016/S0379-0738(01)00511-4Search in Google Scholar
76 Coulter DA HJ, Prince DA. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol 1989; 25:582–93.10.1002/ana.410250610Search in Google Scholar PubMed
77 Matar KM, Nicholls PJ, Tekle A, Bawazir SA, Al-Hassan MI. Liquid chromatographic determination of six antiepileptic drugs and two metabolites in microsamples of human plasma. Ther Drug Monit 1999; 21:559–66.10.1097/00007691-199910000-00013Search in Google Scholar PubMed
78 Wallace JE, Schwertner HA, Hamilton HE, Shimek EL. Electron-capture gas-liquid chromatographic determination of ethosuximide and desmethylmethsuximide in plasma or serum. Clin Chem 1979; 25:252–5.10.1093/clinchem/25.2.252Search in Google Scholar
79 van der Kleijn E, Collste P, Norlander B, Agurell S, Sjoqvist F. Gas chromatographic determination of ethosuximide and phensuximide in plasma and urine of man. J Pharm Pharmacol 1973; 25:324–7.10.1111/j.2042-7158.1973.tb10016.xSearch in Google Scholar PubMed
80 Speed DJ, Dickson SJ, Cairns ER, Kim ND. Analysis of six anticonvulsant drugs using solid-phase extraction, deuterated internal standards, and gas chromatography-mass spectrometry. J Anal Toxicol 2000; 24:685–90.10.1093/jat/24.8.685Search in Google Scholar PubMed
81 White HS, Wolf HH, Swinyard EA, Skeen GA, Sofia RD. A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia 1992; 33:564–72.10.1111/j.1528-1157.1992.tb01711.xSearch in Google Scholar PubMed
82 Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acid A receptors. Ann Neurol 1994; 35:229–34.10.1002/ana.410350216Search in Google Scholar PubMed
83 Johannessen SI, Battino D, Berry DJ, Bialer M, Kramer G, Tomson T, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003; 25:347–63.10.1097/00007691-200306000-00016Search in Google Scholar PubMed
84 Palmer KJ, McTavish D. Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993; 45:1041–65.Search in Google Scholar
85 Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 2002; 24:91–103.10.1097/00007691-200202000-00016Search in Google Scholar PubMed
86 Richens A, Banfield CR, Salfi M, Nomeir A, Lin CC, Jensen P, et al. Single and multiple dose pharmacokinetics of felbamate in the elderly. Br J Clin Pharmacol 1997:129–34.10.1046/j.1365-2125.1997.00642.xSearch in Google Scholar
87 Troupin AS, Montouris G, Hussein G. Felbamate: therapeutic range and other kinetic information. J Epilepsy 1997; 10:26–31.10.1016/S0896-6974(96)00063-1Search in Google Scholar
88 Gur P, Poklis A, Saady J, Costantino A. Chromatographic procedures for the determination of felbamate in serum. J Anal Toxicol 1995; 19:499–503.10.1093/jat/19.6.499Search in Google Scholar
89 Poquette MA. Isothermal gas-chromatographic method for the rapid determination of felbamate concentration in human serum. Ther Drug Monit 1995; 17:168–73.10.1097/00007691-199504000-00011Search in Google Scholar
90 Juenke JM, Brown PI, McMillin GA, Urry FM. Procedure for the monitoring of gabapentin with 2,4,6-trinitrobenzene sulfonic acid derivatization followed by HPLC with ultraviolet detection. Clin Chem 2003; 49:1198–201.10.1373/49.7.1198Search in Google Scholar
91 Guttuso T, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 2003; 361:1703–5.10.1016/S0140-6736(03)13365-XSearch in Google Scholar
92 Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996; 39:95–9.10.1002/ana.410390114Search in Google Scholar
93 Tomson T, Johannessen SI. Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol 2000; 55:697–705.10.1007/s002280050001Search in Google Scholar
94 Wilson EA, Sills GJ, Forrest G, Brodie MJ. High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. Epilepsy Res 1998; 29:161–6.10.1016/S0920-1211(97)00078-8Search in Google Scholar
95 Wilson JM. The case for monitoring gabapentin. Ther Toxins News 2004; 19:1–4.Search in Google Scholar
96 Kushnir MM, Crossett J, Brown PI, Urry FM. Analysis of gabapentin in serum and plasma by solid-phase extraction and gas chromatography-mass spectrometry for therapeutic drug monitoring. J Anal Toxicol 1999; 23:1–6.10.1093/jat/23.1.1Search in Google Scholar PubMed
97 Wolf CE, Saady JJ, Poklis A. Determination of gabapentin in serum using solid-phase extraction and gas-liquid chromatography. J Anal Toxicol 1996; 20:498–501.10.1093/jat/20.6.498Search in Google Scholar
98 Krivanek P, Koppatz K, Turnheim K. Simultaneous isocratic HPLC determination of vigabatrin and gabapentin in human plasma by dansyl derivatization. Ther Drug Monit 2003; 25:374–7.10.1097/00007691-200306000-00019Search in Google Scholar
99 Donaldson JA, Glauser TA, Olberding LS. Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox Gastaut syndrome). Epilepsia 1997; 38:68–73.10.1111/j.1528-1157.1997.tb01079.xSearch in Google Scholar
100 Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997; 43:457–64.10.1046/j.1365-2125.1997.00594.xSearch in Google Scholar
101 May TW, Rambeck B, Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 1996; 18:523–31.10.1097/00007691-199610000-00001Search in Google Scholar
102 Battino D, Croci D, Granata T, Mamoli D, Messina S, Perucca E. Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication. Ther Drug Monit 2001; 23:217–22.10.1097/00007691-200106000-00006Search in Google Scholar
103 Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001; 47:151–4.10.1016/S0920-1211(01)00305-9Search in Google Scholar
104 Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000; 38:191–204.10.2165/00003088-200038030-00001Search in Google Scholar
105 Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK lamotrigine/carbamazepine monotherapy trial group. Lancet 1995; 345:476–9.10.1016/S0140-6736(95)90581-2Search in Google Scholar
106 Morris RG, Black AB, Harris AL, Batty AB, Sallustio BC. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 1998; 46:547–51.10.1046/j.1365-2125.1998.00835.xSearch in Google Scholar PubMed PubMed Central
107 George S, Wood AJ, Braithwaite RA. Routine therapeutic monitoring of lamotrigine in epileptic patients using a simple and rapid high performance liquid chromatographic technique. Ann Clin Biochem 1995; 32:584–8.10.1177/000456329503200611Search in Google Scholar
108 Lensmeyer GL, Gidal BE, Wiebe DA. Optimized highperformance liquid chromatographic method for determination of lamotrigine in serum with concomitant determination of phenytoin, carbamazepine, and carbamazepine epoxide. Ther Drug Monit 1997; 19:292–300.10.1097/00007691-199706000-00009Search in Google Scholar
109 Ramachandran S, Underhill S, Jones SR. Measurement of lamotrigine under conditions measuring phenobarbitone, phenytoin, and carbamazepine using reversed-phase high-performance liquid-chromatography at dual wavelengths. Ther Drug Monit 1994; 16:75–82.10.1097/00007691-199402000-00013Search in Google Scholar
110 Watelle M, Demedts P, Franck F, DeDeyn PP, Wauters A, Neels H. Analysis of the antiepileptic phenyltriazine compound lamotrigine using gas chromatography with nitrogen phosphorus detection. Ther Drug Monit 1997; 19:460–4.10.1097/00007691-199708000-00016Search in Google Scholar
111 Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia 2001; 42:13–8.10.1046/j.1528-1157.2001.00003.xSearch in Google Scholar
112 Hadjikoutis S, Pickersgill TP, Smith PE. Drug points: weight loss associated with levetiracetam. Br Med J 2003; 327:905.10.1136/bmj.327.7420.905Search in Google Scholar
113 Loscher W, Honack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 1993; 232:147–58.10.1016/0014-2999(93)90768-DSearch in Google Scholar
114 Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000; 85:77–85.10.1016/S0163-7258(99)00052-2Search in Google Scholar
115 Walker MC, Patsalos PN. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 1995; 67:351–84.10.1016/0163-7258(95)00021-6Search in Google Scholar
116 Nicolas JM, Collart P, Gerin B, Mather G, Trager W, Levy R, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos 1999; 27:250–4.Search in Google Scholar
117 Perucca E, Gidal BE, Ledent E, Baltes E. Levetiracetam does not interact with other antiepileptic drugs. Epilepsia 2000; 41S:254.Search in Google Scholar
118 Sharief MK, Singh P, Sander LWAS, Partsalos PN, Shorvon SD. Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy. J Epilepsy 1996; 9:106–12.10.1016/0896-6974(96)00010-2Search in Google Scholar
119 May TW, Rambeck B, Jurgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 2003; 25:690–9.10.1097/00007691-200312000-00007Search in Google Scholar
120 Ratnaraj N, Doheny HC, Patsalos PN. A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb L059) in serum or plasma by high performance liquid chromatography. Ther Drug Monit 1996; 18:154–7.10.1097/00007691-199604000-00008Search in Google Scholar
121 Vermeij TA, Edelbroek PM. High-performance liquid chromatographic and megabore gas-liquid chromatographic determination of levetiracetam (ucb L059) in human serum after solid-phase extraction. J Chromatogr B Biomed Appl 1994; 662:134–9.10.1016/0378-4347(94)00393-9Search in Google Scholar
122 Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994; 35:S10–3.10.1111/j.1528-1157.1994.tb05938.xSearch in Google Scholar
123 White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000; 41:S17–20.10.1111/j.1528-1157.2000.tb02165.xSearch in Google Scholar
124 Calabresi P, Demurtas M, Stefani A, Pisani A, Sancesario G, Mercuri NB, et al. Action of GP-47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia 1995; 36:990–6.10.1111/j.1528-1157.1995.tb00957.xSearch in Google Scholar
125 Volosov A, Xiaodong S, Perucca E, Yagen B, Sintov A, Bialer M. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 1999; 66:547–53.10.1053/cp.1999.v66.103170001Search in Google Scholar
126 Jung H, Noguez A, Mayet L, Fuentes I, Gonzalez-Esquivel DF. The distribution of 10-hydroxy carbazepine in blood compartments. Biopharm Drug Dispos 1997; 18:17–23.10.1002/(SICI)1099-081X(199701)18:1<17::AID-BDD997>3.0.CO;2-RSearch in Google Scholar
127 Tecoma ES. Oxcarbazepine. Epilepsia 1999; 40:S37–46.10.1111/j.1528-1157.1999.tb00918.xSearch in Google Scholar
128 Hossain M, Sallas W, Gasparini M, D’Souza J. Drug-drug interaction profile of oxcarbazepine in children and adults. Neurology 1999; 52:A525.Search in Google Scholar
129 Sabers A, Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 2000; 60:23–33.10.2165/00003495-200060010-00003Search in Google Scholar
130 Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res 1999; 34:1–41.10.1016/S0920-1211(98)00108-9Search in Google Scholar
131 May TW, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 1999; 21:175–81.10.1097/00007691-199904000-00007Search in Google Scholar
132 Loiseau P. Treatment of concomitant illnesses in patients receiving anticonvulsants – drug interactions of clinical significance. Drug Saf 1998; 19:495–510.10.2165/00002018-199819060-00006Search in Google Scholar
133 Rouan MC, Lecaillon JB, Godbillon J, Menard F, Darragon T, Meyer P, et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 1994; 47:161–7.10.1007/BF00194967Search in Google Scholar
134 Perucca E. The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia 1999; 40:S7–13.10.1111/j.1528-1157.1999.tb02088.xSearch in Google Scholar
135 Elyas AA, Goldberg VD, Patsalos PN. Simple and rapid microanalytical high-performance liquid-chromatographic technique for the assay of oxcarbazepine and its primary active metabolite 10-hydroxycarbazepine. J Chromatogr 1990; 528:473–9.10.1016/S0378-4347(00)82406-8Search in Google Scholar
136 Rouan MC, Souppart C, Alif L, Moes D, Lecaillon JB, Godbillon J. Automated analysis of a novel antiepileptic compound, cgp-33-101, and its metabolite, cgp-47-292, in body fluids by high-performance liquid-chromatography and liquid-solid extraction. J Chromatogr B Biomed Appl 1995; 667:307–13.10.1016/0378-4347(95)00026-FSearch in Google Scholar
137 Levert H, Odou P, Robert H. LC determination of oxcarbazepine and its active metabolite in human serum. J Pharm Biomed Anal 2002; 28:517–25.10.1016/S0731-7085(01)00684-7Search in Google Scholar
138 Richens A. Interactions with antiepileptic drugs. Drugs 1977; 13:266–75.10.2165/00003495-197713040-00002Search in Google Scholar PubMed
139 Hauptman A. Luminal bei Epilepsie. Muench Med Wochenschr 1912; 59:1907–9.Search in Google Scholar
140 Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989; 25:213–20.10.1002/ana.410250302Search in Google Scholar PubMed
141 Scharpé S, Totté J, Neels H, Verkerk R. Enkele farmakokinetische gegevens in verband met de evaluatie van plasmaspiegels van anti-epileptica. Tijdschr Geneeskd 1981; 37:405–9.Search in Google Scholar
142 Goullé JP, Noyon J, Layet A, Rapoport NF, Vaschalde Y, Pignier Y, et al. Phenobarbital in hair and drug monitoring. Forensic Sci Int 1995; 70:191–202.10.1016/0379-0738(94)01619-GSearch in Google Scholar
143 Merritt HH, Putnam TJ. A new series of anticonvulsant drugs tested by experiments on animals. Arch Neurol Psychiatry 1938; 39:1003–15.10.1001/archneurpsyc.1938.02270050129007Search in Google Scholar
144 Merritt HH, Putnam TJ. Sodium diphenyl hydantoinate in treatment of convulsive disorders. J Am Med Assoc 1938; 111:1068–73.10.1001/jama.1938.02790380010004Search in Google Scholar
145 Yaari Y, Pincus JH, Argov Z. Depression of synaptic transmission by diphenylhydantoin. Ann Neurol 1977; 1:334–8.10.1002/ana.410010405Search in Google Scholar PubMed
146 Selzer ME. Action of phenytoin on a composite electrical-chemical synapse in lamprey spinal cord. Ann Neurol 1978; 3:202–6.10.1002/ana.410030304Search in Google Scholar PubMed
147 Tozer TN, Winter ME. Phenytoin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring, 3rd ed. Vancouver WA: Applied Therapeutics, 1992:25–44.Search in Google Scholar
148 Dager WE, Inciardi JF, Howe TL. Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia. Ann Pharmacother 1995; 29:667–70.10.1177/106002809502907-802Search in Google Scholar PubMed
149 de Haan GJ, Carpay JA, van Donselaar CA. Antiepileptic primidone shortly to be withdrawn from sale: change medication now. Ned Tijdschr Geneeskd 2003; 147:2325–6.Search in Google Scholar
150 Moffat AC, Osselton MD, Widdop B, Galichet LY. Clarke’s analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material. Pharmaceutical Press, 2004.Search in Google Scholar
151 Adkins JC, Noble S. Tiagabine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998; 55:437–60.10.2165/00003495-199855030-00013Search in Google Scholar PubMed
152 Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers – potential in the treatment of epilepsy. CNS Drugs 2001; 15:339–50.10.2165/00023210-200115050-00001Search in Google Scholar PubMed
153 Brodie MJ. Tiagabine pharmacology in profile. In: Tiagabine The Art of Epilepsy Care. Proceedings of the 21st International Epilepsy Congress, Australia, Sep 2, 1995. Epilepsia 1995;36 Suppl 6:57–9.10.1111/j.1528-1157.1995.tb06015.xSearch in Google Scholar PubMed
154 Bopp B, Gustavson L, Johnson M, Hightower B, Mulford D, Curry T, et al. Pharmacokinetics and metabolism of C-14 tiagabine HCl after oral administration to human subjects. Epilepsia 1995; 36:S158.10.1111/j.1528-1157.1995.tb02575.xSearch in Google Scholar PubMed
155 Samara EE, Gustavson LE, El-Shourbagy T, Locke C, Granneman GR, Sommerville KW. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy. Epilepsia 1998; 39:868–73.10.1111/j.1528-1157.1998.tb01182.xSearch in Google Scholar
156 So EL, Wolff D, Graves NM, Leppik IE, Cascino GD, Pixton GC, et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res 1995; 22:221–6.10.1016/0920-1211(95)00048-8Search in Google Scholar
157 Mengel HB, Houston A, Back DJ. An evaluation of the interaction between tiagabine and an oral contraceptive in female volunteers. J Pharm Med 1994; 4:141–50.Search in Google Scholar
158 Rowan AJ, Gustavson LE, Shu V, Sommerville KW. Drug concentration relationships in a multicentre tiagabine (Gabitril™) trial. Epilepsia 1997; 38:40.Search in Google Scholar
159 Chollet DF, Castella E, Goumaz L, Anderegg G. Gas chromatography-mass spectrometry assay method for the therapeutic drug monitoring of the antiepileptic drug tiagabine. J Pharm Biomed Anal 1999; 21:641–6.10.1016/S0731-7085(99)00167-3Search in Google Scholar
160 Gustavson LE, Chu SY. High-performance liquid-chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection. J Chromatogr 1992; 574:313–8.10.1016/0378-4347(92)80045-RSearch in Google Scholar
161 Cleton A, de Greef HJ, Edelbroek PM, Voskuyl RA, Danhof M. Stereoselective central nervous system effects of the R- and S-isomers of the GABA uptake blocker N-(4,4-di-(3-methylthien-2-yl)but-3-enyl) nipecotic acid in the rat. Br J Pharmacol 1999; 128:1651–8.10.1038/sj.bjp.0702962Search in Google Scholar PubMed PubMed Central
162 Lamb EJ, Stevens PE, Nashef L. Topiramate increases biochemical risk of nephrolithiasis. Ann Clin Biochem 2004; 41:166–9.10.1258/000456304322880104Search in Google Scholar PubMed
163 Langtry HD, Gillis JC, Davis R. Topiramate – a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997; 54:752–73.10.2165/00003495-199754050-00009Search in Google Scholar PubMed
164 Rosenfeld WE, Liao S, Kramer LD, Anderson G, Palmer M, Levy RH, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997; 38:324–33.10.1111/j.1528-1157.1997.tb01124.xSearch in Google Scholar PubMed
165 Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997; 38:317–23.10.1111/j.1528-1157.1997.tb01123.xSearch in Google Scholar PubMed
166 Patsalos PN. The pharmacokinetic profile of topiramate. Rev Contemp Pharmacother 1999; 10:155–62.Search in Google Scholar
167 Levy RH, Bishop F, Streeter AJ, Trager WF, Kunze KL, Thummel KT, et al. Explanation and prediction of drug interactions with topiramate using a Cyp450 inhibition spectrum. Epilepsia 1995; 36:252.Search in Google Scholar
168 Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000; 41:977–80.10.1111/j.1528-1157.2000.tb00282.xSearch in Google Scholar PubMed
169 Lhatoo SD, Wong ICK, Sander J. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 2000; 41:338–41.10.1111/j.1528-1157.2000.tb00165.xSearch in Google Scholar
170 Twyman RE, Ben-Menachem E, Veloso F, Bomhof MAM, Wu SC, Pledger G. Plasma topiramate (TPM) concentration vs. therapeutic response during monotherapy. Epilepsia 1999; 40:111–2.Search in Google Scholar
171 Holland ML, Uetz JA, Ng KT. Automated capillary gaschromatographic assay using flame ionization detection for the determination of topiramate in plasma. J Chromatogr 1988; 433:276–81.10.1016/S0378-4347(00)80608-8Search in Google Scholar
172 Riffitts JM, Gisclon LG, Stubbs RJ, Palmer ME. A capillary gas chromatographic assay with nitrogen phosphorus detection for the quantification of topiramate in human plasma, urine and whole blood. J Pharm Biomed Anal 1999; 19:363–71.10.1016/S0731-7085(98)00137-XSearch in Google Scholar
173 Tang PH, Miles MV, Glauser TA, Coletta L, Doughman N, Doose D, et al. An improved gas chromatography assay for topiramate monitoring in pediatric patients. Ther Drug Monit 2000; 22:195–201.10.1097/00007691-200004000-00010Search in Google Scholar
174 Contin M, Riva R, Albani F, Baruzzi A. Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma. J Chromatogr B Biomed Sci Appl 2001; 761:133–7.10.1016/S0378-4347(01)00302-4Search in Google Scholar
175 Christensen J, Hojskov CS, Poulsen JH. Liquid chromatography tandem mass spectrometry assay for topiramate analysis in plasma and cerebrospinal fluid: validation and comparison with fluorescence-polarization immunoassay. Ther Drug Monit 2002; 24:658–64.10.1097/00007691-200210000-00013Search in Google Scholar
176 Sodium valproate. Lancet 1988; ii:1229–31.10.1016/S0140-6736(88)90815-XSearch in Google Scholar
177 MacDonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1993; 34:S1–8.10.1111/j.1528-1157.1993.tb05918.xSearch in Google Scholar PubMed
178 McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986; 237:1001–11.Search in Google Scholar
179 Triggs WJ, Bohan TP, Lin SN, Willmore LJ. Valproate-induced coma with ketosis and carnitine insufficiency. Arch Neurol 1990; 47:1131–3.10.1001/archneur.1990.00530100101021Search in Google Scholar PubMed
180 Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37:379–85.10.1212/WNL.37.3.379Search in Google Scholar
181 Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 1989; 39:201–7.10.1212/WNL.39.2.201Search in Google Scholar
182 Thomson AH, Brodie MJ. Pharmacokinetic optimization of anticonvulsant therapy. Clin Pharmacokinet 1992; 23:216–30.10.2165/00003088-199223030-00004Search in Google Scholar
183 Matsumoto I, Kuhara T, Yoshino M. Metabolism of branched medium chain length fatty acid. II. β-Oxidation of sodium dipropylacetate in rats. Biomed Mass Spectrom 1976; 3:235–40.10.1002/bms.1200030509Search in Google Scholar
184 Goulden KJ, Dooley JM, Camfield PR, Fraser AD. Clinical valproate toxicity induced by acetylsalicylic acid. Neurology 1987; 37:1392–4.10.1212/WNL.37.8.1392Search in Google Scholar
185 Gupta RN, Eng F, Gupta ML. Gas-chromatographic analysis for valproic acid as phenacyl esters. Clin Chem 1979; 25:1303–5.10.1093/clinchem/25.7.1303Search in Google Scholar
186 Gupta RN, Keane PM, Gupta ML. Valproic acid in plasma, as determined by liquid chromatography. Clin Chem 1985; 25:1984–5.10.1093/clinchem/25.11.1984Search in Google Scholar
187 Libeer J, Scharpé S, Schepens P, Verkerk R. Gas chromatographic analysis of sodium di-n-propylacetate in human plasma. J Chromatogr 1978; 160:285–7.10.1016/S0021-9673(00)91808-9Search in Google Scholar
188 Nau H, Wittfoht W, Schafer H, Jakobs C, Rating D, Helge H. Valproic acid and several metabolites–quantitative determination in serum, urine, breast milk and tissues by gas chromatography-mass spectrometry using selected ion monitoring. J Chromatogr 1981; 226:69–78.10.1016/S0378-4347(00)84207-3Search in Google Scholar
189 Malmgren K, Ben-Menachem E, Frisen L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 2001; 42:609–15.10.1046/j.1528-1157.2001.28600.xSearch in Google Scholar PubMed
190 Hardus P, Verduin WM, Postma G, Stilma JS, Berendschot T, van Veelen CWM. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia 2000; 41:581–7.10.1111/j.1528-1157.2000.tb00212.xSearch in Google Scholar PubMed
191 Zackon DH, Racette L, Daneshwar H, Kertes PJ, Guberman A. Visual field loss associated with vigabatrin. Invest Ophthalmol Vis Sci 1999; 40:S656.Search in Google Scholar
192 Gatti G, Bartoli A, Marchiselli R, Michelucci R, Tassinari CA, Pisani F, et al. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. Br J Clin Pharmacol 1993; 36:603–6.10.1111/j.1365-2125.1993.tb00422.xSearch in Google Scholar
193 Gram L, Lyon BB, Dam M. Gamma-vinyl-GABA: a single-blind trial in patients with epilepsy. Acta Neurol Scand 1983; 68:34–9.10.1111/j.1600-0404.1983.tb04812.xSearch in Google Scholar
194 Chollet DF, Goumaz L, Juliano C, Anderegg G. Fast isocratic high-performance liquid chromatographic assay method for the simultaneous determination of gabapentin and vigabatrin in human serum. J Chromatogr B Biomed Sci Appl 2000; 746:311–4.10.1016/S0378-4347(00)00327-3Search in Google Scholar
195 Ratnaraj N, Patsalos PN. A high-performance liquid chromatography micromethod for the simultaneous determination of vigabatrin and gabapentin in serum. Ther Drug Monit 1998; 20:430–4.10.1097/00007691-199808000-00013Search in Google Scholar
196 Loscher W, Fassbender CP, Gram L, Gramer M, Horstermann D, Zahner B, et al. Determination of GABA and vigabatrin in human plasma by a rapid and simple HPLC method – correlation between clinical response to vigabatrin and increase in plasma GABA. Epilepsy Res 1993; 14:245–55.10.1016/0920-1211(93)90049-DSearch in Google Scholar
197 George S, Gill L, Braithwaite RA. Simple high-performance liquid chromatographic method to monitor vigabatrin, and preliminary review of concentrations determined in epileptic patients. Ann Clin Biochem 2000; 37:338–42.10.1258/0004563001899249Search in Google Scholar
198 Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the fifth Eilat conference (EILAT V). Epilepsy Res 2001; 43:11–58.10.1016/S0920-1211(00)00171-6Search in Google Scholar
199 Seino M, Miyazaki H, Ito T. Zonisamide. Epilepsy Res 1991; 3S:169–74.Search in Google Scholar
200 Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kiuchi M, Kitada M. Characterization of human liver microsomal cytochrome-P450 involved in the reproductive metabolism of zonisamide. Mol Pharmacol 1993; 44:216–21.Search in Google Scholar
201 McJilton JS, Ramsay RE, Vasquez D, Wilder BJ, Sachellarcs C, Browne T. Pharmacokinetics of zonisamide: results from a randomized double-blind multi-center placebo controlled study. Epilepsia 2000; 41:224.Search in Google Scholar
202 Ojemann LM, Shastri RA, Wilensky AJ, Friel PN, Levy RH, McLean JR, et al. Comparative pharmacokinetics of zonisamide (Ci-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit 1986; 8:293–6.10.1097/00007691-198609000-00010Search in Google Scholar PubMed
203 Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 1998; 20:593–7.10.1097/00007691-199812000-00001Search in Google Scholar PubMed
204 Wilensky AJ, Friel PN, Ojemann LM, Dodrill CB, McCormick KB, Levy RH. Zonisamide in epilepsy – a pilot study. Epilepsia 1985; 26:212–20.10.1111/j.1528-1157.1985.tb05408.xSearch in Google Scholar PubMed
205 Leppik IE. Zonisamide. Epilepsia 1999; 40:S23–9.10.1111/j.1528-1157.1999.tb00916.xSearch in Google Scholar
206 Mattson RH. Antiepileptic drug-monitoring – a reappraisal. Epilepsia 1995; 36:S22–9.10.1111/j.1528-1157.1995.tb06006.xSearch in Google Scholar
207 Juergens U. Simultaneous determination of zonisamide and 9 other antiepileptic drugs and metabolites in serum – a comparison of microbore and conventional high-performance liquid-chromatography. J Chromatogr 1987; 385:233–40.10.1016/S0021-9673(01)94635-7Search in Google Scholar
208 Furuno K, Oishi R, Gomita Y, Eto K. Simple and sensitive assay of zonisamide in human serum by high-performance liquid chromatography using a solid-phase extraction technique. J Chromatogr B Biomed Appl 1994; 656:456–9.10.1016/0378-4347(94)00132-4Search in Google Scholar
209 Shimoyama R, Ohkubo T, Sugawara K. Monitoring of zonisamide in human breast milk and maternal plasma by solid-phase extraction HPLC method. Biomed Chromatogr 1999; 13:370–2.10.1002/(SICI)1099-0801(199908)13:5<370::AID-BMC900>3.0.CO;2-5Search in Google Scholar
210 Berry DJ. Determination of zonisamide (3-sulphamoyl-methyl-1,2-benzisoxazole) in plasma at therapeutic concentrations by high-performance liquid chromatography. J Chromatogr 1990; 534:173–81.10.1016/S0378-4347(00)82159-3Search in Google Scholar
211 Makino K, Goto Y, Sueyasu M, Futagami K, Kataoka Y, Oishi R. Micellar electrokinetic capillary chromatography for therapeutic drug monitoring of zonisamide. J Chromatogr B Biomed Sci Appl 1997; 695:417–25.10.1016/S0378-4347(97)00185-0Search in Google Scholar
212 Baselt RC. Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications, 2002.Search in Google Scholar
213 Stringer JL. Drugs for seizure disorders (epilepsies). In: Brody TM, Larner J, Minneman KP, editors. Human pharmacology, molecular to clinical, 3rd ed. St Louis: Mosby, 1998:376.Search in Google Scholar
© Walter de Gruyter
